An analysis of germline-somatic interactions in breast cancer tumors revealed novel associations relevant to the disease’s progression and treatment resistance. For example, the study presented at the 2021 San Antonio Breast Cancer Symposium (SABCS) showed that carriers of the BRCA2 mutation had inferior outcomes to treatment with first-line CDK4/6 inhibitors plus endocrine therapy. This could…
Liquid biopsies were used to determine whether ctDNA analysis was predictive of disease progression in women with HR+/HER2- breast cancer.
A prospective study sought to determine the significance of race on the risk of developing lymphedema and disease severity in women with breast cancer.
Researchers presented updated findings from the DESTINY-Breast03 trial.
The researchers found that targeted therapies matched to genomic alterations in ESCAT tier I/II significantly improved progression-free survival.
Elacestrant showed a statistically significant and clinically meaningful progression-free survival improvement compared with standard of care.
This meta-analysis was conducted on data from 4 clinical trials including more than 7000 women with ER+ breast cancer.
A subgroup analysis of the KEYNOTE-355 trial sought to determine which patients with metastatic TNBC would benefit from treatment with pembrolizumab and chemotherapy.
Eight patients had a complete response within 1 month of infusion.
The model appears to predict minimal residual disease status.
